Abbott Labs Files 8-K on Operations and Financials
Ticker: ABT · Form: 8-K · Filed: Jul 18, 2024 · CIK: 1800
| Field | Detail |
|---|---|
| Company | Abbott Laboratories (ABT) |
| Form Type | 8-K |
| Filed Date | Jul 18, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, financial-condition, operations
Related Tickers: ABT
TL;DR
Abbott Labs filed its 8-K for July 18, 2024, covering operations and financials. No major surprises yet.
AI Summary
Abbott Laboratories filed an 8-K on July 18, 2024, to report on its results of operations and financial condition, as well as to file financial statements and exhibits. The filing does not contain specific financial figures or details about operational changes, but serves as a formal notification of these items to the SEC.
Why It Matters
This filing is a routine update for investors and the market, indicating that Abbott Laboratories is providing necessary financial and operational information as required by regulatory bodies.
Risk Assessment
Risk Level: low — This is a standard regulatory filing with no new material information or significant events disclosed.
Key Players & Entities
- ABBOTT LABORATORIES (company) — Registrant
- July 18, 2024 (date) — Date of Report
- Illinois (location) — State of Incorporation
- 100 Abbott Park Road (address) — Principal executive offices
FAQ
What specific financial results or operational updates are being reported by Abbott Laboratories in this 8-K filing?
The filing indicates that it pertains to 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits,' but it does not provide specific figures or details within the provided text.
What is the exact date of the earliest event reported in this 8-K?
The date of the earliest event reported is July 18, 2024.
Under which section of the Securities Exchange Act of 1934 is this 8-K report filed?
This 8-K report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What is Abbott Laboratories' principal executive office address?
Abbott Laboratories' principal executive office is located at 100 Abbott Park Road, Abbott Park, Illinois 60064-6400.
What is the IRS Employer Identification Number for Abbott Laboratories?
The IRS Employer Identification Number for Abbott Laboratories is 36-0698440.
Filing Stats: 634 words · 3 min read · ~2 pages · Grade level 14.2 · Accepted 2024-07-18 07:37:35
Filing Documents
- abt-20240718.htm (8-K) — 28KB
- abt-2024q2xexhibitx991.htm (EX-99.1) — 856KB
- abbottlogoa.jpg (GRAPHIC) — 7KB
- 0001628280-24-032182.txt ( ) — 1091KB
- abt-20240718.xsd (EX-101.SCH) — 2KB
- abt-20240718_def.xml (EX-101.DEF) — 15KB
- abt-20240718_lab.xml (EX-101.LAB) — 26KB
- abt-20240718_pre.xml (EX-101.PRE) — 16KB
- abt-20240718_htm.xml (XML) — 4KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition On July 18, 2024, Abbott Laboratories announced its results of operations for the second quarter 2024. Furnished as Exhibit 99.1, and incorporated herein by reference, is the news release issued by Abbott announcing those results. In that news release, Abbott uses various non-GAAP financial measures including, among others, net earnings excluding specified items. These non-GAAP financial measures adjust for factors that are unusual or unpredictable, such as expenses primarily associated with acquisitions, a divestiture, restructuring actions, cost reduction initiatives, fair value adjustments to the contingent consideration related to business acquisitions, impairment charges related to intangible assets or equity investments, certain regulatory costs, tax benefits associated with specified items, net tax expense as a result of the resolution of various tax positions related to prior years, and excess tax benefits associated with share-based compensation. These non-GAAP financial measures also exclude intangible amortization expense to provide greater visibility on the results of operations excluding these costs, similar to how Abbott's management internally assesses performance. Abbott's management believes the presentation of these non-GAAP financial measures provides useful information to investors regarding Abbott's results of operations as these non-GAAP financial measures allow investors to better evaluate ongoing business performance. Abbott's management also uses these non-GAAP financial measures internally to monitor performance of the businesses. Abbott, however, cautions investors to consider these non-GAAP financial measures in addition to, and not as a substitute for, financial measures prepared in accordance with GAAP.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits Exhibit No. Exhibit 99.1 Press Release dated July 18, 2024 (furnished pursuant to Item 2.02). 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ABBOTT LABORATORIES Date: July 18, 2024 By: /s/ Philip P. Boudreau Philip P. Boudreau Executive Vice President, Finance and Chief Financial Officer